European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury.
The European Medicines Agency conducted a nine-month investigation into so-called GLP-1s, which have skyrocketed in demand over the last year. The review examined several drugs from Novo Nordisk, including Wegovy and Ozempic, but did not include Eli Lilly's Zepbound and Mounjaro.into so-called GLP-1s, a blockbuster class of treatments that mimic a hormone produced in the gut to suppress a person's appetite. Those drugs have skyrocketed in demand over the last year despite their hefty price tags and spotty insurance coverage.'s Zepbound and Mounjaro, two versions of the same drug sold for weight loss and diabetes.
Semaglutide is the active ingredient used in Wegovy, Ozempic and Novo Nordisk's diabetes pill Rybelsus. Liraglutide is the active ingredient in Novo Nordisk's older weight loss drug Saxenda. The probe also included other active ingredients in older weight loss and diabetes drugs, including dulaglutide, exenatide and lixisenatide.
The EMA on Friday said it analyzed results from a large U.S. study and did not find a direct association between the use of semaglutide and suicidal thoughts. Results from another study conducted by the agency also did not support a link between GLP-1 drugs and the risk of suicidal thoughts.Moderna halts plans to build Kenya vaccine plant as Covid shot demand plungesMontgomery County
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ScienceAlert - 🏆 63. / 68 Read more »
Source: NBCLA - 🏆 319. / 59 Read more »
Source: 10News - 🏆 732. / 50 Read more »
Source: ABC - 🏆 471. / 51 Read more »
Source: ForbesTech - 🏆 318. / 59 Read more »
Source: Forbes - 🏆 394. / 53 Read more »